Lilly Oncology President to Retire

Sue Mahony

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

The president of Lilly Oncology has announced plans to retire. Indianapolis-based Eli Lilly and Co. says Sue Mahony will step down from the role at the end of August after 18 years with the company.

Mahony also serves as senior vice president of Lilly and a member of Lilly’s executive committee. She joined the company in 2000 and has held senior leadership roles in product development, marketing and general management.

The company says Mahony led Lilly Oncology through a number of milestones, including the integration of ImClone, the launch of several key brands such as Verzenio, and the recently-announced refocusing of Lilly’s oncology research and development strategy.

"What I’ve appreciated over the years is the opportunity to participate in something greater than myself," said Mahony. "We make medicines that help patients with cancer live longer. What a privilege it’s been to wake up each morning with that as my life’s work."

Lilly says it is considering candidates from both inside and outside the company to succeed Mahony.